AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03586518 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac explantation
Description: A limited post-mortem will be performed to retrieve patients' hearts for preparation and storage at St George's University, London where direct comparison will be made between levels of scarring seen directly under the microscope between that on the MRI scans.
Study NCT03586518 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 48-Hour continuous cardiac monitoring
Description: Attach continuous Holter monitor (Schiller, medilog®AR12 plus/AR4 plus/FD5 plus, Baar, Switzerland) that will start before dialysis and terminate just before the subsequent dialysis treatment 48h later.
Study NCT03586518 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: Collect blood samples from the arterial needle before dialysis. Approximately 30 millilitres of blood will be collected and then be pipetted into cryotubes and frozen at -80°C in an electronically monitored freezer for analysis in batches throughout the study. These samples will be used to investigate the relationship between circulating biomarkers of fibrosis, the MRI scans and the histological samples.
Study NCT04111107 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Next Gen Sequencing Report
Description: 1) Next Gen Sequencing report obtained as Standard of Care within the past 12 months of enrollment date will be used. If more than one report exists in this time period, the most recent report will be used.
Study NCT01839201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: No psychological intervention
Study NCT01839201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: suggestion
Description: In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.
Study NCT01839201 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dreamfilm
Description: In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.
Study NCT00605059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]AV94
Description: Evaluation of \[123I\] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
Study NCT04461353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerolized Hydroxychloroquine Sulfate
Description: sterile AHCQ 100 mg/mL for inhalation, is a clear solution packaged in clear glass vials and stored at room temperature.
Study NCT04461353 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product and diluent solution is sodium chloride inhalation solution, United States Pharmacopeia (USP) 0.9%.
Study NCT02509273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Study NCT04105569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent-Induced Biofilm Overgrowth
Description: Customized acrylic dental (sextant) stent will be used during brushing for 21 days to influence reversible gingival tissue inflammation.
Study NCT00764478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: asenapine tablet, 5 mg sublingually BID for 21 days
Study NCT00764478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: asenapine tablet, 10 mg sublingually BID for 21 days
Study NCT00764478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo sublingual tablet, administered BID for 21 days
Study NCT02029495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 210 mg brodalumab
Description: 210 mg brodalumab administered via subcutaneous injection
Study NCT02029495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg brodalumab
Description: 140 mg brodalumab administered via subcutaneous injection
Study NCT02029495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via subcutaneous injection until week 24.
Study NCT03335618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Monitoring and Symptom Coaching
Description: Triggered check-ins by study personnel to keep participants on track to meet fitness goals
Study NCT03335618 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Passive Activity Monitoring
Description: Passive step tracking without check-ins
Study NCT03603834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI
Description: mFOLFOXIRI consists of the following combination of drugs:~1. Oxaliplatin, 85 mg/m2, IV over 2 hours~2. Leucovorin, 400 mg/m2, IV over 2 hours~3. Irinotecan, 150 mg/m2, IV over 90 minutes~4. 5 FU, 400 mg/m2, IV bolus~5. 5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection~each 14 day cycle, for 6 cycles
Study NCT02103452 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian and endometrial samples
Description: Ovarian and endometrial samples were evaluated by hematoxlin \&amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE
Study NCT02555657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Study NCT02555657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study NCT02555657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eribulin
Study NCT02555657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Study NCT02555657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vinorelbine
Study NCT02435550 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Molecular diagnostic testing
Description: Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.
Study NCT05792748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulp hemostasis with a dry cotton pellet
Description: Application of a dry cotton pellet, then the chamber was filled with ZOE directly over the pulp
Study NCT05792748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulp hemostasis with a wet cotton pellet impregnated with FS
Description: Application of a a wet cotton pellet impregnated with FS, then the chamber was filled with ZOE directly over the pulp
Study NCT05792748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stainless steel crown
Description: Stainless steel crown placed as a final restoration
Study NCT03665428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAMB treatment (modified quadruple therapy)
Description: Randomly assign either as PAMB or PBMT group treatment
Study NCT03665428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PBMT treatment (bismuth-containing quadruple therapy)
Description: Randomly assign either as PAMB or PBMT group treatment
Study NCT03411057 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Description: An interactive form of meditation that includes gentle yoga.
Study NCT03411057 — intervention group
Intervention type: OTHER
Intervention: Control
Description: Standard of care including an educational video.
Study NCT00843843 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bright light box
Description: Bright light of about 5000 lux, administered while sitting at a desk.
Study NCT03463096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High G acceleration on a long-arm human centrifuge
Description: Gx (chest-to-back) and Gz (head-to-toe)
Study NCT01609179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPI-926
Description: IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.
Study NCT04540081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epic Healthy Planet Population Health Module
Description: Electronic population health module which is tailored to increased adherence to USPSTF and CDC recommendations
Study NCT02207556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Doxycycline will be continued until one of the following criteria is met:~* Patient has completed 1 year of doxycycline therapy~* Patient develops any grade 3-4 toxicity related to doxycycline use.
Study NCT03011450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: K-877
Study NCT03011450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K-877
Study NCT03101319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 cholecalciferol
Description: As mentioned in the description of the study arm
Study NCT03011450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Study NCT03011450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for K-877)
Study NCT02756975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: coaxial prostate biopsy
Description: In this method, a larger introducing needle is needed for the puncture. The introducing needle is placed over the perineum. The biopsy needle is inserted throughout the introducing needle.Then, the direction of the biopsy is changed by tilting the coaxial needle. The investigator needs to puncture the prostate capsule only once for sampling at each each side of the prostate (right and left sides).
Study NCT02756975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noncoaxial prostate biopsy
Description: In this method, there is no introducing needle. Biopsy needle is inserted repeatedly for each tissue sampling (at least fourteen times). A smaller biopsy needle is used for the puncture in this method.~The main disadvantage of the coaxial technique is that a larger introducing needle is needed for the puncture (12). On the other whand, the advantage of noncoaxial method is that the needle is within the prostate for only a few seconds to document needle position with ultrasonography before firing
Study NCT03101319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B Complex Oral Tablet
Description: As mentioned in the description of the study arm
Study NCT04217109 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Odour sampling
Description: Upon receipt of the samples at the Institute Curie-Paris, the compresses will be packed in jars and then transmitted to the dog center and analyzed by the study dogs.~Positive marking is characterized by a sitting position of the dog in front of the sample.
Study NCT01303445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aggrenox alone
Description: Aggrenox 1 capsule twice daily for 7 days
Study NCT01303445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggrenox and omeprazole
Description: Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
Study NCT01303445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole alone
Description: omeprazole 80 once daily for 7 days
Study NCT01247064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized 3% saline
Description: 4 mL of nebulized 3% saline once
Study NCT01247064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized 0.9% Normal Saline
Description: 4 mL of 0.9% nebulized normal saline once
Study NCT00947635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary intervention - supplements
Description: Supplement bar \& spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels
Study NCT00924807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate, Bicalutamide, Sorafenib
Description: Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg
Study NCT02381626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine sample
Description: PAH (Polycyclic Aromatic Hydrocarbon) will be assessed via urine sample collection of Urinary 1 hydroxy pyrene and particulate matter collected via Polyurethane Foam Filter (PUF) sampler
Study NCT03848169 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Radiofrequency
Description: See previous page
Study NCT03848169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: See previous page
Study NCT00292188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: pregabalin
Study NCT00292188 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02010788 — intervention group
Intervention type: BIOLOGICAL
Intervention: botulinum toxin Type A
Description: Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
Study NCT01408628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Insulin Education
Description: Offer and assess the safety and effectiveness of a synchronous (live) interactive 4-week Internet course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve an HbA1c of \< 7.0% using an established treat-to-target algorithm.
Study NCT03132194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPSG 7.5%
Description: topical gel
Study NCT03132194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aczone
Description: topical gel
Study NCT00977158 — intervention group
Intervention type: PROCEDURE
Intervention: Throat Swab
Description: Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
Study NCT01871324 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: group therapy
Study NCT02509273 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study NCT00985023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Steel screw fixation of Lisfranc fracture-dislocation.
Description: Stainless steel screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
Study NCT04192305 — intervention group
Intervention type: PROCEDURE
Intervention: LPV
Description: LPV means tidal volume of 6 ml/kg, inspiratory-expiratory (I/E) ratio of 1/1, positive end expiratory pressure (PEEP) minimum 5 cmH20 and higher during laparoscopy in obese patients, Inspiratory oxygen concentration (FIO2) 40 % during maintenance and extubation while also giving CPAP. Lung recruitment maneuver (LRM) when lung compliance decreases below 40 ml/cmH2O.
Study NCT04192305 — intervention group
Intervention type: PROCEDURE
Intervention: routine LV
Description: Give volume en frequency as required by end tidal carbon dioxide, PEEP and LRM only when saturation drops intra operative, no requirement to use low FIO2 and CPAP during extubation.
Study NCT03132194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical gel
Study NCT05011630 — intervention group
Intervention type: OTHER
Intervention: Pancreaticoduodenectomy
Description: The incidece of IAA after pancreaticoduodectomy; to validate the risk factors of IAA
Study NCT01727882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief feedback
Description: A brief feedback was given on the results of the daily assessments, including a recommendation to the paroled offender and a email report was sent to the probation officer.
Study NCT01727882 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily assessments
Description: Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
Study NCT02617771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
Study NCT01727882 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily assessments
Description: Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
Study NCT04667260 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Maxillary sinus membrane elevation
Description: Maxillary sinus membrane elevation with blood coagulum
Study NCT04667260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus membrane elevation
Description: Maxillary sinus membrane elevation with blood coagulum
Study NCT04667260 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Maxillary sinus floor augmentation
Description: Maxillary sinus floor augmentation with 1:1 autogenous bone graft and deprotinized porcine bone mineral
Study NCT04667260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maxillary sinus floor augmentation
Description: Maxillary sinus floor augmentation with 1:1 autogenous bone graft and deprotinized porcine bone mineral
Study NCT00914459 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Moroctocog alfa ( AF-CC)
Description: Dosing is at the discretion of the Investigator
Study NCT00914459 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laboratory tests
Description: Factor VIII PK samples, Hematology, Chemistry and Coagulation testing, FactorVIII Inhibitor and Anti Factor VIII antibody
Study NCT03064074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresolimumab
Description: The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.
Study NCT00413439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: Intravenous solution or oral capsules
Study NCT03465527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrednisoLONE 50 MG
Description: Prednisolone 50mg bid po or iv (equivalent dose of other steroid) for 5 days ± 2 days
Study NCT01239758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-031 (Extension of cohort 1 from core study, A031-03)
Description: ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
Study NCT01239758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-031 (Extension of cohort 2 from core study, A031-03)
Description: Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.
Study NCT01239758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-031 (Extension of cohort 3 from core study, A031-03)
Description: Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
Study NCT04504786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitality acupunch (VA) exercise program
Description: The VA had three phases and took 40 minutes to complete.
Study NCT04504786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants maintained their daily activities.
Study NCT03176654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVLAT manipulation
Description: HVLAT will be performed 10 minutes after the first blood draw.
Study NCT03176654 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham HVLAT manipulation
Description: Sham HVLAT will be performed 10 minutes after the first blood draw.
Study NCT03504423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI 613, mFolfirinox
Description: CPI-613: 500mg/m2, IV infusion at a rate of 4mL/min via a central venous port. mFolfirinox: given immediately after CPI-613 administration
Study NCT03504423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfirinox
Description: Folfirinox
Study NCT00985023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Absorbable screw fixation of Lisfranc fracture-dislocations.
Description: Bioabsorbable (poly-levo-lactic acid) screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
Study NCT01340612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: endovascular coiling with any type of currently approved coil (first or second generation)
Description: Standard procedure for endovascular coiling.Coils may be bare Platinum coils or any so-called second generation coils such as but not restricted to Hydrocoil or Cerecyte
Study NCT01424397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-705498
Description: 12mg intranasal
Study NCT01424397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP
Description: 200ug intranasal